entecavir has been researched along with Multiple-Myeloma* in 3 studies
1 review(s) available for entecavir and Multiple-Myeloma
| Article | Year |
|---|---|
Hepatitis B reverse seroconversion despite entecavir prophylaxis in a myeloma patient on multiple novel agents: a case report and review of the literature.
Topics: Antiviral Agents; DNA, Viral; Guanine; Hepatitis B; Hepatitis B e Antigens; Hepatitis B virus; Humans; Multiple Myeloma; Seroconversion; Treatment Outcome | 2021 |
2 other study(ies) available for entecavir and Multiple-Myeloma
| Article | Year |
|---|---|
Clearance of HBsAg in a patient with familial multiple myeloma after a bortezomib-based regimen combined with anti-HBV drug: A case report.
Reactivation of hepatitis B virus (HBV) after treatment with bortezomib-based regimens in HBV-positive patients with multiple myeloma (MM) has been reported in the past few years. Nevertheless, there is evidence of inhibition of HBV replication by bortezomib in transgenic mice. However, there is still no clinical evidence that bortezomib inhibits HBV.. A 55-year-old MM patient with a family history of MM, who was also a chronic HBV carrier, achieved HBV clearance after treatment with a bortezomib-based regimen in combination with anti-HBV drugs.. The diagnosis was MM with chronic carrier of HBV.. He received bortezomib-based regimen for MM as well as entecavir as a prophylaxis to prevent HBV reactivation.. This patient achieved HBsAg and HBV-DNA clearance after 2 months and the remission was maintained during the next 2 years. He also achieved complete remission of MM and underwent consolidation therapy with autologous hematopoietic stem cell transplantation.. This is the first case of MM with HBV clearance after receiving a bortezomib-based regimen combined with anti-HBV drug. Research on related mechanisms might provide new suggestions and hope for better management of HBV positive patients with MM and for the treatment of HBV patients. Topics: Antineoplastic Agents; Antiviral Agents; Bortezomib; Clinical Protocols; Drug Therapy, Combination; Guanine; Hematopoietic Stem Cell Transplantation; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Multiple Myeloma; Transplantation, Autologous; Treatment Outcome | 2020 |
Reactivation of hepatitis B virus without core antibody.
We present the case of a male patient not vaccinated against hepatitis B virus (HBV) and with reactivity to a surface antibody who, after immunosuppression for a multiple myeloma, had HBV reactivation. Pharmacological HBV suppression was tried, but viremia could not be suppressed. Production-detection core mutations or immunity issues can explain this clinical phenomenon. Topics: Antiviral Agents; Guanine; Hematopoietic Stem Cell Transplantation; Hepatitis B; Hepatitis B Antibodies; Hepatitis B Core Antigens; Hepatitis B virus; Humans; Male; Middle Aged; Multiple Myeloma | 2015 |